Tempus AI sells AI-enabled precision medicine services, including genomic testing and data licensing to drug developers. Revenue of USD 411.5 million rose 23%, gross profit rose 27% and adjusted EBITDA reached USD 25.6 million. The net loss of USD 14.9 million compares with USD …
Key HighlightsTeradyne (NASDAQ:TER) was trading down 6.8% at USD 245.84 on Friday, November 13, 2026, in market data, and no company announcement for November 11 to 13 explaining the move was found.Third-quarterRevenuewas USD 1.306 billion, up 70% from USD 769 million a year earlier …
Digital asset revenue fell to USD 13.2 million from USD 43.4 million, while lease revenue from high-performance computing rose to USD 63.0 million from USD 7.2 million. Total debt was about USD 5.2 billion, including USD 1.63 billion of long-term convertible notes and USD …
The Land and Resource Management segment produced USD 201.6 million of revenue, USD 166.3 million ofOperating Incomeand USD 133.8 million of net income. Water Services and Operations added USD 71.8 million of revenue, USD 41.5 million of operating income and USD 33.6 million of …
Revenue grew about 21% to USD 1.981 billion, gross paymentVolumerose 20% to USD 61.8 billion, and subscription andFintechGross Profitrose 29% to USD 630 million.Operating Incomewas USD 165 million against USD 84 million, adjusted EBITDA was USD 240 million against USD 176 million, and freeCash …
Key HighlightsTOP Financial Group (NASDAQ:TOP) was trading up 5.7% at USD 16.31 on Friday, November 13, 2026, in market data, and no company announcement dated November 12 or 13 explaining the move was found.On November 3, 2026, the company said it was not aware …
Tower is a specialty analog foundry that makes chips for customers, and it is also listed in Tel Aviv.Gross Profitwas USD 178.8 million, up about 92% from a year earlier, operating profit excluding non-recurring items was USD 127.1 million against USD 50.6 million a …
Key HighlightsUniti Group (NASDAQ:UNIT) was trading up 5.12% at USD 4.52 on Friday, November 13, 2026, in market data, and no company announcement dated November 12 or 13 explaining the move was found.Third-quarterRevenuewas USD 848.1 million, adjusted EBITDA was USD 289.3 million, and the …
Vir develops antibody and small interfering RNA medicines. ECLIPSE 1 enrolled 124 adults with chronic hepatitis delta, randomized 2 to 1 to monthly subcutaneous injections of tobevibart and elebsiran or delayed treatment. At week 48, 79% of treated patients had undetectable hepatitisDeltavirus against 0% …
Bookings of USD 10.3 million were up 87% from USD 5.5 million in the second quarter. Backlog was USD 27.6 million at September 30, 2026, made up of USD 14.1 million ofCapitalorders, USD 3.9 million of service and USD 9.6 million of STEP contracts. …